Tenvie Therapeutics begins Phase 1 study of new brain-penetrating drug
Tenvie Therapeutics announced on 13 October 2026 that it has dosed the first subject in a Phase 1 first-in-human study of TNV313. The randomized ascending dose trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses in healthy volunteers
<p>Tenvie Therapeutics announced on 13 October 2026 that it has dosed the first subject in a Phase 1 first-in-human study of TNV313. The randomized ascending dose trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses in healthy volunteers </p>